Beyond FDA: Healthcare AI Adoption in the U.S.

A 12-part series on what MedTech AI companies learn too late about the U.S. market: why FDA clearance does not guarantee adoption, and how reimbursement, clinical validation, key opinion leaders, interoperability and hospital IT governance decide whether a cleared product gets used.

12 articles in this series, in reading order

  1. Beyond FDA · Part 1 of 12

    What MedTech Founders Learn Too Late About U.S. Healthcare

    FDA clearance answers whether a product can be marketed. Hospitals ask why they should adopt it. The first lesson in the series: clearance is not market access.

    2 min read

  2. Beyond FDA · Part 2 of 12

    Why Great AI Products Fail Without A Reimbursement Strategy

    A great product is not a business until someone can pay for it. Why reimbursement, economic value and the hospital CFO decide the fate of many AI tools.

    2 min read

  3. Beyond FDA · Part 3 of 12

    Why Clinical Validation Is Becoming More Important Than AI Accuracy

    Hospitals now ask whether they can trust a model in their own environment. Why clinical validation is overtaking benchmark accuracy as the real differentiator.

    2 min read

  4. Beyond FDA · Part 4 of 12

    Why Key Opinion Leaders Matter More Than Marketing In Healthcare AI

    Marketing rarely sells healthcare AI; clinicians vouching to other clinicians does. What key opinion leaders actually provide, and why investors watch it too.

    3 min read

  5. Beyond FDA · Part 5 of 12

    Clinical Validation, KOLs, and FDA: Three Very Different Things

    FDA clearance, clinical validation and clinical adoption answer three different questions for three different audiences. Why conflating them stalls healthcare AI companies.

    2 min read

  6. Beyond FDA · Part 6 of 12

    Interoperability Is The Most Underrated Competitive Advantage In Healthcare AI

    A slightly less accurate AI that fits PACS, RIS and EHR will often beat a better one that needs workarounds. What interoperability actually requires, item by item.

    2 min read

  7. Beyond FDA · Part 7 of 12

    Why CIOs Buy Integration Before Innovation

    Deals often die in IT security review, not in clinical evaluation. CIOs buy risk reduction, and products need to be built for that question from the start.

    2 min read

  8. Beyond FDA · Part 8 of 12

    Healthcare AI's Biggest Bottleneck Isn't AI. It's Interoperability.

    By deployment, the model is the easy part. PACS approval, EHR data governance and infrastructure decide the go-live date, and few teams budget time for them.

    2 min read

  9. Beyond FDA · Part 9 of 12

    Why ACR Alignment Is Becoming A Competitive Advantage For AI Vendors

    "Is this aligned with ACR guidance?" is now a buying-committee question in radiology. Why ACR alignment carries weight even though it is not a legal requirement.

    2 min read

  10. Beyond FDA · Part 10 of 12

    What AI Vendors Often Miss About ACR Standards

    ACR alignment is about how radiology practices, not only detection rates. Reporting structure, follow-up and workflow expectations that AI vendors tend to overlook.

    2 min read

  11. Beyond FDA · Part 11 of 12

    PCCP May Be The Biggest Regulatory Shift In Healthcare AI Since 510(k)

    The Predetermined Change Control Plan lets AI models change within a pre-agreed plan instead of a new submission each time. Why it may be the biggest shift since the 510(k).

    3 min read

  12. Beyond FDA · Part 12 of 12

    The Four Pillars Of Healthcare AI Adoption

    The series in one frame: stalled pilots and products that never scaled trace back to four pillars. FDA clearance, clinical validation, interoperability and reimbursement.

    3 min read

Back to all Insights